drugset
drugset / Trial / NCT02042014

Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan

NCT02042014 ↗

Phase 3 Completed 8 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

To provide continued treatment to Pulmonary Arterial Hypertension (PAH) patients who are benefitting from treatment with QTI571.

Timeline

Start
2014-01-22
Primary completion
2016-10-17
Completion
2016-10-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Imatinib Small molecule 200 mg Oral
Subject Imatinib Small molecule 400 mg Oral

Indications

pulmonary arterial hypertension